Identification and management of toxicities from immune checkpoint-blocking drugs.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

The blockade of immune checkpoints in cancer immunotherapy

2012 • 12,062 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2012 • 7,361 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

2014 • 2,071 citations

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

2014 • 1,704 citations

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

2011 • 1,452 citations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

2014 • 1,382 citations

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

2012 • 1,353 citations

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 • 953 citations

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 • 812 citations

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

2007 • 612 citations

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

2009 • 551 citations

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

2010 • 501 citations

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

2013 • 406 citations

Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

2011 • 373 citations

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

2010 • 284 citations

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

2014 • 277 citations

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

2010 • 230 citations

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

2013 • 225 citations

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

2013 • 225 citations

Ipilimumab: controversies in its development, utility and autoimmune adverse events

2009 • 223 citations

Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

2008 • 219 citations

Mitigating the toxic effects of anticancer immunotherapy

2014 • 202 citations

Ipilimumab in patients with cancer and the management of dermatologic adverse events

2014 • 176 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

2013 • 169 citations

Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management

2010 • 167 citations

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

2013 • 154 citations

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

2011 • 152 citations

Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma

2014 • 149 citations

Ipilimumab-Associated Colitis: CT Findings

2013 • 143 citations

The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis

2013 • 132 citations

Neurological immune-related adverse events of ipilimumab

2013 • 127 citations

Ipilimumab-induced acute severe colitis treated by infliximab

2013 • 126 citations

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

2011 • 118 citations

Ipilimumab-Induced Hypophysitis: MR Imaging Findings

2009 • 106 citations

Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease

2012 • 77 citations

Severe meningo-radiculo-nevritis associated with ipilimumab

2012 • 67 citations

Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy

2013 • 51 citations

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.

2013 • 42 citations

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

2009 • 29 citations

Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide

2012 • 19 citations

Real-world impact of education: treating patients with ipilimumab in a community practice setting

2013 • 19 citations

Hepatotoxicity of Immunosuppressive Drugs

2013 • 16 citations

Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.

2014 • 5 citations